Medicine and Health Sciences Commons^™

Olanzapine Treatment And Time-Dependent Changes Of Hypothalamic Ampk-Acc-Cpt1 Signalling, Food Intake And Body Weight In Rats, Meng He, Q Zhang, H Wang, Jiamei Lian, C Deng, Xu-Feng Huang

Xu-Feng Huang

No abstract provided.

Time-Dependant Alterations Of Hypothalamic Energy Regulatory Network By Olanzapine In Rats, Q Zhang, M He, Hongqin Wang, J Lian, C Deng, Xu-Feng Huang

Xu-Feng Huang

Abstract of a paper that presented at the Australian Neuroscience Society 32nd Annual meeting.

Novel Olanzapine Analogues Presenting A Reduced H1 Receptor Affinity And Retained 5ht2a/D2 Binding Affinity Ratio, Somayeh Jafari, Marc E. Bouillon, Xu-Feng Huang, Stephen G. Pyne, Francesca Fernandez-Enright

Xu-Feng Huang

Background Olanzapine is an atypical antipsychotic drug with high clinical efficacy, but which can cause severe weight gain and metabolic disorders in treated patients. Blockade of the histamine 1 (H1) receptors is believed to play a crucial role in olanzapine induced weight gain, whereas the therapeutic effects of this drug are mainly attributed to its favourable serotoninergic 2A and dopamine 2 (5HT2A/D2) receptor binding affinity ratios. Results We have synthesized novel olanzapine analogues 8a and 8b together with the already known derivative 8c and we have examined their respective in vitro affinities for the 5HT2A, D2, and H1 receptors. Conclusions …

Reducing Olanzapine-Induced Weight Gain Side-Effect By Using Betahistine: A Study In The Rat Model, Chao Deng, Jiamei Lian, Nagesh Brahmavar Pai, Xu-Feng Huang

Xu-Feng Huang

Olanzapine is effective at treating multiple domains of schizophrenia symptoms. However, it induces serious metabolic side effects. Antipsychotic drug’s antagonistic affinity to histamine H1 receptors has been identified as a main contributor for weight gain/obesity side effects. This study therefore investigated whether a combined treatment of betahistine (a H1 receptor agonist and H3 receptor antagonist) could reduce the body weight/obesity induced by olanzapine. Female Sprague Dawley rats were treated orally with olanzapine (1 mg/kg, t.i.d.) and/or betahistine (2.67 mg/kg, t.i.d.), or vehicle for two weeks. Rats treated with olanzapine exhibited significant body weight gain and increased food intake. Co-treatment of …

Preventing And Treating Olanzapine-Induced Obesity With Betahistine: A Chronic Animal Model Study, Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng

Xu-Feng Huang

Objective : Olanzapine, an atypical antipsychotic drug, is widely prescribed to treat schizophrenia, but induces serious weight gain/ obesity side-effects. Antipsychotic drugs antagonistic affinity for histamine H1 receptors is the main indicator of weight gain side-effects. This study aimed to investigate whether chronic treatment with betahistine (H1 receptor agonist/H3 receptor antagonist) could prevent/ treat olanzapine-induced weight gain at different stages of treatment.

Methods : Female Sprague-Dawley rats were administered under 5 conditions (n=12) : (1) Rats were treated with vehicle (control) during whole experimental period ; (2) ‘‘Obesity treatment group’’ : 5 weeks olanzapine treatment (1 mg/kg, t.i.d.), followed by …